0001127602-16-059384.txt : 20160803 0001127602-16-059384.hdr.sgml : 20160803 20160803134828 ACCESSION NUMBER: 0001127602-16-059384 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160801 FILED AS OF DATE: 20160803 DATE AS OF CHANGE: 20160803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Medtronic plc CENTRAL INDEX KEY: 0001613103 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 000000000 FISCAL YEAR END: 0424 BUSINESS ADDRESS: STREET 1: 20 ON HATCH, LOWER HATCH STREET CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: 01135314381700 MAIL ADDRESS: STREET 1: 20 ON HATCH, LOWER HATCH STREET CITY: DUBLIN STATE: L2 ZIP: 2 FORMER COMPANY: FORMER CONFORMED NAME: Medtronic Ltd DATE OF NAME CHANGE: 20150112 FORMER COMPANY: FORMER CONFORMED NAME: Medtronic Holdings Ltd DATE OF NAME CHANGE: 20140711 FORMER COMPANY: FORMER CONFORMED NAME: Kalani I Ltd DATE OF NAME CHANGE: 20140709 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kuntz Richard CENTRAL INDEX KEY: 0001341125 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36820 FILM NUMBER: 161803277 MAIL ADDRESS: STREET 1: MEDTRONIC, INC. STREET 2: 710 MEDTRONIC PWKY MS LC 310 CITY: MINNEAPOLIS STATE: MN ZIP: 55432 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2016-08-01 0001613103 Medtronic plc MDT 0001341125 Kuntz Richard 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 1 SrVP & Chief Scien, Clin, Reg Ordinary Shares 2016-08-01 4 A 0 9842 0 A 118801 D Stock Option (Right to Buy) 88.06 2016-08-01 4 A 0 39368 0 A 2017-08-01 2026-08-01 Ordinary Shares 39368 39368 D Stock Option (Right to Buy) 88.06 2016-08-01 4 A 0 1136 0 A 2017-08-01 2026-08-01 Ordinary Shares 1136 1136 D The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2019 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. /s/ Rhonda L. Ingalsbe, Attorney-in-fact 2016-08-03